Search clinical trials for: KEYTRUDA

Total 1323 results

Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Nectin Therapeutics Ltd
Merck Sharp & Dohme LLC

Recruiting

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Cancer | Metastatic Cancer | Advanced Solid Tumor | Tumor, Solid | Locally Advanced Solid Tumor

United States, Israel
University of Colorado, Denver
Merck Sharp & Dohme LLC

Recruiting

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Gastric Cancer | GastroEsophageal Cancer

United States
Epitopoietic Research Corporation

Not yet recruiting

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Glioma, Malignant

Thailand
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Olaparib in LA-HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Rutgers, The State University of New Jersey

Recruiting

ATATcH Alternating Treatment Plans for Advanced Cancer

Head and Neck Cancer | Lung Cancer

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States
Amunix, a Sanofi Company
Merck Sharp & Dohme LLC

Recruiting

To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Locally Advanced or Metastatic HER2-Expressing Cancers

Australia, Spain, France, Portugal
National Cancer Institute (NCI)

Recruiting

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
Imugene Limited

Recruiting

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)

Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Bile Duct Cancer | Advanced Solid Tumor | Solid Tumor, Adult | Solid Carcinoma

United States, Australia
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States
RenJi Hospital

Not yet recruiting

IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation (iPLENTY-pvtt)

Hepatocellular Carcinoma | Liver Transplant; Complications | Liver Cancer | Portal Vein Thrombosis | Radiotherapy; Complications

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma

United States
BiOneCure Therapeutics Inc.

Recruiting

A Study in Patients With Advanced Cancers

Cancer | Advanced Solid Tumor | Advanced Cancer | Oncology

United States
Fujifilm Pharmaceuticals U.S.A., Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors

Advanced Solid Tumor

United States
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, Taiwan, China, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
Yale University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

T-Cell Lymphoma

United States
Evaxion Biotech A/S
Merck Sharp & Dohme LLC

Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Australia
Providence Health & Services
Merck Sharp & Dohme LLC; Eisai Inc.

Recruiting

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Melanoma, Uveal

United States
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Elizabeth K. Lee MD
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Gynecologic Cancer | Ovarian Clear Cell Carcinoma

United States
National Taiwan University Hospital

Not yet recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Unresectable Hepatocellular Carcinoma | Pembrolizumab | Stereotactic Body Radiotherapy | Lenvatinib

Taiwan
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004) (HYPERION)

Esophageal Squamous Cell Carcinoma

China
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac

Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Melanoma | Squamous Cell Carcinoma of Head and Neck

United States, Australia, Denmark, Spain, France, Germany
M.D. Anderson Cancer Center
STRATEGIC ALLIANCE: Merck

Recruiting

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Adenocarcinoma | Tumor

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Hokkaido University Hospital
Merck Sharp & Dohme LLC

Recruiting

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

Effect of Drug

Japan
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Colorectal Neoplasms

China
Mayo Clinic

Recruiting

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Human Papillomavirus-Related Carcinoma | Locally Advanced Oropharyngeal Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
University of Southampton
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE)

Diffuse Large B Cell Lymphoma

United Kingdom
Pfizer
Eli Lilly and Company; Merck Sharp & Dohme LLC; Merck KGaA, Darmstadt, Germany

Recruiting

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)

Metastatic Colorectal Cancer

United States, Denmark, Spain, Australia, France, Italy, Belgium, Slovakia, Canada, Czechia, Germany, Netherlands, Norway, Poland, Sweden, United Kingdom
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Seagen Inc.

Recruiting

A Study of SGN-PDL1V in Advanced Solid Tumors

Melanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell Carcinoma

United States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands
Antengene Therapeutics Limited
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Australia, China
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Plasma Cell Myeloma

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo
Merk Sharp & Dohme España S.A.

Recruiting

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA)

Metastatic Colorectal Cancer

Spain
Haider Mahdi
Dr. Reddys Laboratories, SA

Recruiting

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Epithelial Ovarian Cancer

United States
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; Curis, Inc.

Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Stomach Cancer | Gastric Cancer | Esophageal Cancer | Gastroesophageal Junction Cancer | Esophagus Cancer

United States
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Triple Negative Breast Cancer

China
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Viracta Therapeutics, Inc.

Recruiting

Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Nasopharyngeal Carcinoma | EBV-Related Gastric Carcinoma | EBV-Related Leiomyosarcoma | EBV Related Carcinoma | EBV-Related Sarcoma

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Australia, Canada, Malaysia
Kosei Hasegawa, MD, PhD

Recruiting

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Carcinoma, Ovarian Epithelial

Japan
Baylor College of Medicine
Merck Sharp & Dohme LLC; The Methodist Hospital Research Institute

Recruiting

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

United States

Search clinical trials for: KEYTRUDA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations